Home/Pipeline/af-002 (PSW-1025)

af-002 (PSW-1025)

Prostate Cancer (Refractory)

IND-enablingActive

Key Facts

Indication
Prostate Cancer (Refractory)
Phase
IND-enabling
Status
Active
Company

About Alpha Fusion

A Japanese biotech developing targeted alpha therapies using Astatine-211 for precise cancer treatment with minimal side effects.

View full company profile

Therapeutic Areas